Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352092 · ClinicalTrials.gov registry record · Phase 4
Pilot Study for HLA Identical Living Donor Renal Transplant Recipients
A Phase 4 study of Renal Transplant, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00352092 is a Phase 4 study of Renal Transplant that has completed, run by University of Cincinnati. The registered enrollment target is 20 participants, below the 48-participant average among 5 other Renal Transplant trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00352092, a Phase 4 study of Renal Transplant, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of a steroid-free and calcineurin-inhibitor free treatment regimen for patients who are receiving a kidney transplant from a living donor that is HLA-identical (has a similar immune system).
Conditions Studied
Interventions
- DRUG sirolimus
- DRUG mycophenolate mofetil
- DRUG calcineurin inhibitor
Study Locations (1)
Ohio
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2002-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00352092
The ClinicalTrials.gov registry entry for NCT00352092 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 48-participant average among 5 other Renal Transplant trials with a reported enrollment target (58% lower). The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Transplant appearing as the primary indexed condition, and to 3 interventions - of which sirolimus is the first listed.
NCT00352092 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00352092 about?
NCT00352092 is a clinical study titled "Pilot Study for HLA Identical Living Donor Renal Transplant Recipients". The purpose of this study is to evaluate the safety and effectiveness of a steroid-free and calcineurin-inhibitor free treatment regimen for patients who are receiving a kidney transplant from a living donor that is HLA-identical (has a similar immune system).
What is the current status of trial NCT00352092?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2002-06. Estimated completion is 2007-12.
What conditions does trial NCT00352092 study?
This clinical trial studies the following conditions: Renal Transplant.
What interventions are being tested in trial NCT00352092?
The interventions under investigation include: sirolimus (DRUG), mycophenolate mofetil (DRUG), calcineurin inhibitor (DRUG).
Who is sponsoring clinical trial NCT00352092?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00352092 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Outcomes in Stable Renal Transplant Patients Switched FromTacrolimus to Envarsus XR™
ACTIVE NOT RECRUITING · Phase 4
-
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
ACTIVE NOT RECRUITING · Phase 2
-
Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)
COMPLETED
-
"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"
COMPLETED · Phase 2
-
The Use of ACE Inhibitors in the Early Renal Post-transplant Period
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.